FUNDING
Key Metrics
Total funding
$430M
As of Jul 30, 2026Value Add Pulse research
Company Snapshot
Ollin Biosciences is a Biotech company, based in Chicago, Illinois, founded 2023. Total funding $430M (As of Jul 30, 2026).
Recent changes
- Jul 30, 2026Jul 30, 2026First reported total funding: $430M Value Add Pulse enrichment
- Jun 26, 2026Jun 26, 2026Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics Pipeline Pulse story
- Jun 25, 2026Jun 25, 2026Raised $330M Series B Crunchbase News
- Jun 25, 2026Jun 25, 2026New investor: ARCH Venture Partners Crunchbase News
- Jun 25, 2026Jun 25, 2026Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies Pulse story
Earlier changes (1)
- Jun 24, 2026Jun 24, 2026Raised $156.2M SEC EDGAR Form D
Funding History
2 events · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jun 25, 2026 | Series B | $330M | — | ARCH Venture PartnersTCG Crossover outlined = lead | Pulse story |
| Jun 24, 2026 | funding round | $156.2M | — | SEC EDGAR Form D |
Investors
Latest Pulse
- Jun 26, 2026Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics PipelineOllin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.→
- Jun 25, 2026Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease TherapiesOllin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.→
Coverage Timeline
newest firstAll Coverage
FUNDING$330M
Ollin Biosciences Raises $330M Series B to Advance Its Therapeutics Pipeline
Ollin Biosciences raised a $330 million Series B co-led by TCG Crossover and Arch Venture Partners, one of the largest life-sciences rounds of the week. The financing pushes its therapeutics pipeline deeper into clinical development and adds to mounting evidence that biotech's capital markets have reopened in force alongside the AI boom.
FUNDING
Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies
FUNDING$330M
Ollin Biosciences Raises $330M Series B for Next-Generation Eye Disease Therapies
Ollin Biosciences raised a $330 million Series B led by TCG Crossover and ARCH Venture Partners to advance its pipeline of ophthalmic therapies, one of the largest biotech rounds of the period. The deal is a reminder that even amid AI's dominance of headlines and capital, large therapeutic biotech rounds remain a major and resilient corner of venture funding.
Related Companies
Sources & methodologyshow
Where these figures come from
- SEC EDGAR Form Dprimary source1 fact
- Crunchbase Newsresearch database1 fact
- Value Add Pulse researchValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.